Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Immunology Preclinical
France 
Details:
Data presentation based on a preclinical development of a TALEN® based genome editing in T-cells for the treatment of two product candidates targeting primary immunodeficiencies: RAG1 for Severe Combined Immunodeficiency (SCID) and STAT3 for Hyper IgE syndrome.
Lead Product(s): Undisclosed
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Preclinical Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2021
Details:
Arsenic trioxide has the unique property of increasing cellular oxidative stress to the point where it induces cell death of activated cells (enhanced apoptosis). It also has an effect on pro-inflammatory cytokines.
Lead Product(s): Arsenic Trioxide
Therapeutic Area: Immunology Product Name: Arscimed
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 29, 2021
Details:
The poster presentation highlights efficacy results for OSE-230 in chronic inflammatory preclinical models and ex vivo human models.inflammatory preclinical models and ex vivo human models.
Lead Product(s): OSE-230
Therapeutic Area: Immunology Product Name: OSE-230
Highest Development Status: Preclinical Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 30, 2020
